Year Founded
2007
Ownership
Private
Employees
~10
Therapeutic Areas
OncologyImmunologyNeurology
Stage
Phase 1
Modalities
Protein therapeuticsProtein therapeutics

Gliknik General Information

Two clinical-stage programs: GL-2045 (IVIG replacement) and GL-0719 (complement pathway inhibitor) in Phase 1 trials

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office

Drug Pipeline

GL-2045
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Gliknik's pipeline data

Book a demo

Key Partnerships

Pfizer

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Gliknik Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Gliknik's complete valuation and funding history, request access »

Gliknik Investors

First In Ventures (FIV)
Investor Type: Venture Capital
Holding: Minority
SAISO Partners
Investor Type: Venture Capital
Holding: Minority
RDA Ventures
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »